Food allergies affect over 17M people in Europe and increasing at a 2 digit prevalence rate. With no cure, the only successful method to prevent allergic reactions is to strictly avoid all foods containing the allergen. Hence, to identify these, the consumers rely on an accurate product labelling.The labelling of allergen contents for the industry is however not trivial, it does not only depend on the composition of the product, but also on the possible cross-contamination with allergens from other products. The current lack of standardized food allergen control plans and cost-effective allergen testing tools, drives food manufacturers to adopt over cautious labelling strategies. As a result, 90% of products with ¨may contain¨ allergen labels do not contain any. This reduces the choice of safe food for the allergic population (39.1M people), leading to a risk taking behaviour. SaPher project will disrupt the food allergen assessment market thanks to the development of an allergen assessment procedure supported by the industrialization and commercial deployment of our full automatic SaPher nano-photonics biosensing allergen test platform. SaPher will simultaneously assess up to 6 different allergens in food matrices, reducing turnaround times and cost by over 70% in comparison with current golden standards. To reach market, we will elaborate a standardized risk assessment method (DTU), develop the antibodies of interest not comercially available in the market for the target industries (INGE), industrialize and optimise our technology for mass production (LUME and UPV) and demonstrate both technology and procedure with the meat, dairy and bakery industries (NESTLE) as well as independent laboratories under operational conditions. As a result, we expect SaPher to be adopted by large and medium food producing companies and external laboratories, ensuring products are correctly labelled on allergen contents by performing over 1,1 Million allergen tests in 3 years.

The ongoing increase of the human population accompanied by growing numbers of livestock to feed this population, as well as human invasion into natural habitats of wild animals makes humans progressively vulnerable to animal pathogens. Global trade as well as climate changes can contribute to pathogen transmission, e.g. through import of infected vectors or expansion of habitats for arthropod vectors such as mosquitoes and midges. Examples for this include recent European outbreaks of the arthropod-borne Dengue, West Nile, Schmallenberg and Usutu viruses in humans, ruminants and birds. Infectious disease outbreaks in animals are often unexpected, but we should be prepared for immediate identification of the causing agent and the evaluation of its pathogenic potential for animals and humans. Preparedness needs expertise in many areas. At surveillance sites early detection and identification of viruses involved in outbreaks is crucial. Screening of different animal species and humans who have been in close contact with (diseased) animals for known or yet undiscovered viruses will also help to be prepared for future outbreaks. Novel viruses in these populations will have to be evaluated for their pathogenicity in susceptibility studies. The HONOURs network will generate new health and scientific knowledge with the aim to locate, identify, characterize, contain, and control infections that are caused by zoonotic agents. The aim of HONOURs is to provide top-quality cross-disciplinary and supra-sectorial training to 15 promising young researchers at the interface of veterinary and human health, virology, biostatistics, and pathogen discovery. These early stage researchers will become “preparedness- experts”.